Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Pentobarbital calcium

March 21, 2017

## Non-proprietary name

Pentobarbital calcium

## Safety measure

Precautions should be revised in the package insert.

In the Important Precautions section regarding drug dependence, the following text should be revised (underlined parts are revised):

Drug dependence may occur due to prolonged use. <u>Long-term use by chronic</u> <u>administration should be avoided. Therapeutic necessity should be carefully considered</u> <u>when continuing administration of this drug.</u>

In the Clinically Significant Adverse Reactions subsection regarding drug dependence of the Adverse Reactions section, the following text should be revised (underlined parts are revised):

Drug dependence: Drug dependence may occur due to prolonged use. Patients should be carefully monitored and <u>caution should be exercised for dosage and treatment duration</u> when administering this drug. Careful attention should be paid especially to patients with alcoholism, tendency to develop drug dependence or medical history of drug dependence, and serious neurosis.

\* This drug is designated as a drug requiring preparation of a Drug Guide for Patients.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>